| 000 | 01376 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250511131638.0 | ||
| 264 | 0 | _c19800426 | |
| 008 | 198004s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSanders, G L | |
| 245 | 0 | 0 |
_aA comparative study of methyldopa and labetalol in the treatment of hypertension. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _c1979 |
||
| 300 |
_a149S-151S p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aBlood Cell Count |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEthanolamines _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xdrug therapy |
| 650 | 0 | 4 |
_aLabetalol _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethyldopa _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aDavies, D M | |
| 700 | 1 | _aGales, G M | |
| 700 | 1 | _aRao, J G | |
| 700 | 1 | _aRawlins, M D | |
| 700 | 1 | _aRoutledge, P A | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 8 _gno. Suppl 2 _gp. 149S-151S |
|
| 999 |
_c414140 _d414140 |
||